文献速递心血管MR

系统性轻链型淀粉样变性的心肌特征、心脏结构与心脏功能

Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2024-07-10

前瞻性纳入80例新诊断系统性轻链(AL)淀粉样变性患者,基线、6个月及12个月(仅AL-CMP)行心脏MRI。细胞外容积(ECV)在全部AL-CMP和47%的AL-non-CMP患者中异常(>32%);ECV与整体纵向应变(GLS)均与主要不良心脏事件(MACE)强相关,并在Mayo分期基础上提升预后价值。

要点

  • ECV>32%见于全部AL-CMP患者及47%的AL-non-CMP患者,可检出亚临床心肌改变。
  • ECV≤32%者无MACE发生,而ECV>48%者74%发生MACE。
  • ECV与GLS均与MACE强相关(P<0.001),加入Mayo分期后预后价值提升(P≤0.002)。

核心结论

  • 在系统性AL淀粉样变性患者中,ECV可检出亚临床心肌改变;治疗后ECV在6个月时趋于升高、12个月时回到与基线无变化的值,而AL-CMP患者GLS在6个月和12个月改善;ECV和GLS在Mayo分期之上提供额外预后价值。

研究设计与样本

  • 前瞻性研究,纳入80例新诊断参与者(中位年龄62岁,58%为男性),依据心脏生物标志物异常和室壁厚度定义AL-CMP与AL-non-CMP,基线及6个月行MRI、AL-CMP患者在12个月再行MRI,Mayo分期基于肌钙蛋白T、N末端B型利钠肽原和游离轻链差值。

关键影像表现/征象

  • ECV>32%见于全部AL-CMP参与者及47%的AL-non-CMP参与者。
  • AL-CMP参与者ECV在6个月时趋于升高(中位+2%;P=0.120),12个月时回到基线值。
  • AL-non-CMP参与者ECV在6个月时中位+2%(P=0.018)。
  • AL-CMP参与者GLS在6个月改善(中位-0.6%;P=0.048)、12个月改善(中位-1.2%;P<0.001)。

诊断标准与关键数值

  • ECV异常定义为>32%。
  • ECV≤32%的参与者无MACE发生,ECV>48%的参与者中74%发生MACE。
  • ECV和GLS与MACE强相关(P<0.001),加入Mayo分期后预后价值提升(P≤0.002)。
  • MACE定义为全因死亡、心力衰竭住院和心脏移植。

临床应用与阅片要点

  • ECV>32%可在心脏生物标志物和室壁厚度尚未满足AL-CMP标准时提示亚临床心肌受累。
  • ECV与GLS可在Mayo分期基础上提供额外预后信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: In systemic light-chain (AL) amyloidosis, cardiac involvement portends poor outcomes.

OBJECTIVES: The authors' objectives were to detect early myocardial alterations, to analyze longitudinal changes with therapy, and to predict major adverse cardiac events (MACE) in participants with AL amyloidosis using cardiac magnetic resonance imaging (MRI).

METHODS: Recently diagnosed participants were prospectively enrolled. AL amyloidosis with and without cardiomyopathy (AL-CMP, AL-non-CMP) were defined based on abnormal cardiac biomarkers and wall thickness. MRI was performed at baseline, 6 months in all participants, and 12 months in participants with AL-CMP. MACE were defined as all-cause death, heart failure hospitalization, and cardiac transplantation. Mayo stage was based on troponin T, N-terminal pro-B-type natriuretic peptide, and difference in free light chains.

RESULTS: This study included 80 participants (median age 62 years, 58% men). Extracellular volume (ECV) was abnormal (>32%) in all participants with AL-CMP and in 47% of those with AL-non-CMP. ECV tended to increase at 6 months (median +2%; AL-CMP P = 0.120; AL-non-CMP P = 0.018) and returned to baseline values at 12 months in participants with AL-CMP. Global longitudinal strain (GLS) improved at 6 months (median -0.6%; P = 0.048) and 12 months (median -1.2%; P < 0.001) in participants with AL-CMP. ECV and GLS were strongly associated with MACE (P < 0.001) and improved the prognostic value when added to Mayo stage (P ≤ 0.002). No participant with ECV ≤32% had MACE, while 74% of those with ECV >48% had MACE.

CONCLUSIONS: In patients with systemic AL amyloidosis, ECV detects subclinical myocardial alterations. With therapy, ECV tends to increase at 6 months and returns to values unchanged from baseline at 12 months, whereas GLS improves at 6 and 12 months in participants with AL-CMP. ECV and GLS offer additional prognostic performance over Mayo stage. (Molecular Imaging of Primary Amyloid Cardiomyopathy [MICA]; NCT02641145).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Clerc OF, Cuddy SAM, Jerosch-Herold M, et al. Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024. PMID: 39001736. doi:10.1016/j.jcmg.2024.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。